TABLE 1.

Therapeutic strategies to target RAS directly in clinical trials

Drug	Study phase	Disease setting	ClinicalTrials.gov identifier	Status
KRAS G12C allele‐specific inhibitors
AMG 510	I/II	Advanced solid tumors	NCT03600883	Recruiting
	II	NSCLC	NCT04625647	Recruiting
	III	NSCLC	NCT04303780	Active, not recruiting
MRTX849	I/II	Advanced solid tumors	NCT03785249	Recruiting
	III	NSCLC	NCT04685135	Recruiting
JAB‐21822	I/II	Advanced solid tumors	NCT05002270	Recruiting
JNJ‐74699157	I	Advanced solid tumors	NCT04006301	Completed
GFH925	I/II	Advanced solid tumors	NCT05005234	Not yet recruiting
YL‐15293	I/II	Advanced solid tumors	NCT05173805	Not yet recruiting
JDQ‐443	I/II	Advanced solid tumors	NCT04699188	Recruiting
	III	NSCLC	NCT05132075	Not yet recruiting
GDC‐6036	I	Advanced solid tumors	NCT04449874	Recruiting
LY3499446	I/II	Advanced solid tumors	NCT04165031	Terminated
LY3537982	I	Advanced solid tumors	NCT04956640	Recruiting
BI 1823911	I	Advanced solid tumors	NCT04973163	Recruiting
D‐1553	I/II	Advanced solid tumors	NCT04585035	Recruiting
Other direct‐targeting RAS inhibitors
AZD4785	I	Advanced solid tumors	NCT03101839	Completed
siG12D LODER	I	PDAC	NCT01188785	Completed
	II	PDAC	NCT01676259	Recruiting
iExosomes	I	PDAC	NCT03608631	Recruiting

Abbreviations: NSCLC, non‐small cell lung carcinoma; PDAC, pancreatic ductal adenocarcinoma